Kornimate/medical-research-clean huggingface dataset:
school nurse-directed secondary obesity prevention for elementary school children

Conditions: Overweight; Obesity

Summary: primary aim: to test the efficacy of an elementary school-based, school nurse-led weight management program to reduce excess weight gain among children, 8 to 12 years old who are overweight and at risk of overweight by increasing healthy dietary practices and physical activity levels and decreasing sedentary practices. primary hypothesis: relative to the control condition, the children receiving the intervention will have a significantly lower body mass index (bmi), following implementation of the 9-month intervention, controlling for baseline values.

primary hypothesis: relative to the control condition, the children receiving the intervention will have a significantly lower body mass index (bmi), following implementation of the 9-month intervention, controlling for baseline values.

Eligibility criteria:
inclusion criteria for child participants: * 3rd 4th and 5th grade student the year the intervention is implemented, * ≥ 8 and ≤ 12 years old, * age- and gender-adjusted bmi ≥ 75th percentile, * child must live in a primary residence with the participating parent exclusion criteria for child participants: * plans to move outside the school district within the next 12 months, * food allergies, * physical limitations, * medical conditions that prohibit participation in the intervention program or measurement, * does not speak and write in english.
treatment of calcific tendinitis by ultrasound-guided needle lavage

Conditions: Calcific Tendinitis

Summary: study population: subjects with long standing symptoms from calcific tendonitis, non-responsive to other forms of conservative treatment study method: a cohort of 50 patients with symptomatic calcific tendonitis will be treated by ultrasound-guided needle lavage. at baseline all study subjects will be assessed by clinical examination, imaging of the shoulder by x-ray and sonography and by the self-report section of the american shoulder and elbow surgeons score (ases). follow-up will be performed after 1 and 4 weeks (score only), 3 (clinical, score, ultrasound, x-ray), 6 and 12 months (score only), and after 24 months (clinical, score, ultrasound, x-ray). patients with insufficient treatment effect will be offered physiotherapy, re-lavage or surgical treatment by acromioplasty. purpose of the study: the investigators want to find out * if shoulder function, measured by a shoulder score, will increase during follow-up * how much of the calcific material can be aspirated (in ml) * to which extend the calcific deposit disappears on x-rays and sonographic images * how many patients will need surgical treatment


Eligibility criteria:
inclusion criteria: * shoulder pain for at least 6 months, localised laterally on the upper humerus * painful arc * positive hawkins test and/or neers tegn for impingement * calcific deposit of \>= 5 mm on shoulder x-ray, verified on sonography with a localisation in the supraspinatus or infraspinatus tendon exclusion criteria: * the presence of other local or systemic diseases affecting shoulder function like arthritis, inflammatory arthropathy or instability * symptoms from a cervical root syndrome * sonographic or mri findings for a rotator cuff tear * earlier surgery in the study shoulder

Keywords: calcific tendinitis shoulder needle lavage ultrasound-guided
impact of bi-26 supplementation on weight gain in underweight infants

Conditions: Underweight; Paediatrics

Summary: the burden of disease experienced by underweight children is significant, particularly in low- and middle-income countries. gut dysbiosis, an imbalance in microbial composition, is thought to play a role in nutrient malabsorption leading to underweight infants and failure to thrive. bifidobacterium longum subspecies infantis (b. infantis) is a commensal bacterial strain important in the breakdown of human milk oligosaccharides (hmos). a decrease in abundance or absence of b. infantis could lead to inadequate hmo processing, elevating intestinal ph and increasing the risk of pathogen overgrowth. bi-26 is a b. infantis probiotic strain that is being evaluated in this study for its impact on weight gain and other health outcomes in underweight infants.


Eligibility criteria:
inclusion criteria: * participant must be between 30 days and 120 days of age (inclusive), at the time of enrollment (study day 1) * hospitalized for acute non-surgical illness * completed acute stabilization phase of treatment, including fluid rehydration and antibiotic course, prior to enrollment (study day 1) * waz at enrollment (study day 1) is less than negative 2 (\<-2) * any sex * participant's parent(s)/legal guardian is capable of giving informed consent which includes agreement to comply with the requirements and restrictions listed in the informed consent form (icf) and in the protocol * participant's parent(s)/legal guardian agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and have no current plans to relocate from the study area for the duration of the study * participant's parent(s)/legal guardian has easy access to reliable refrigeration (for storage of investigational product) * participant receives some feedings from breastmilk and mother intends to continue breastfeeding. exclusion criteria: * congenital condition (suspected or confirmed) that the investigator considers likely to interfere with feeding or with normal growth and development * infant has not been discharged from hospital since birth or has not been at home for at least one week since birth * infant hospitalized with septic shock during current hospitalization * infant required mechanical ventilation during current hospitalization * infant with acute kidney injury on hospital admission * infant with severe jaundice and suspected kernicterus * infant receiving treatment for suspected or confirmed tuberculosis, or suspected or confirmed human immunodeficiency virus (hiv) infection * ongoing infant antibiotic (e.g. as prophylaxis in sickle cell disease) and/or probiotic usage * ongoing maternal antibiotic and/or probiotic usage for breast-feeding infants * inability of participant's parent(s)/legal guardian to comply with protocol requirements, as per investigator assessment.

Keywords: weight-for-age z score underweight infants bifidobacterium longum, b. infantis bi-26 supplementation
study of ravulizumab in immunoglobulin a nephropathy (igan)

Conditions: Immunoglobulin A Nephropathy; IgAN

Summary: the primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in egfr in adult participants with igan who are at risk of disease progression.

the i can study will enroll approximately 510 eligible participants with igan who are high risk of disease progression. participants will be on stable concomitant igan treatment(s) consistent with standard of care for patients with igan for at least 3 months prior to screening. approximately 450 participants will be randomized in a 1:1 allocation ratio to receive a weight-based iv infusion of either ravulizumab or placebo. an interim analysis may be conducted at week 34 to evaluate change in proteinuria and the final analysis will be conducted at week 106 to evaluate egfr. in addition, approximately 60 participants with egfr 20-29 ml/min/1.73m2 will be enrolled in an advanced kidney disease (adkd) cohort after week 106, all participants have the option to enter an open-label ravulizumab access period.

Eligibility criteria:
inclusion criteria: * documentation of igan diagnosis established on kidney biopsy obtained any time prior to or during the screening period for participants with egfr ≥ 30 ml/min/1.73 m\^2. * for participants in the adkd cohorts, egfr 20 to 29 ml/min/1.73 m2 a kidney biopsy is required within 6 months prior to screening or during the screening period. * upcr ≥ 0.75 g/g or up ≥1 g/day calculated from the mean of two 24-hour urine during the screening period. * estimated gfr ≥ 30 ml/min/1.73 m2 at screening. * stable and maximum allowed or tolerated rasi (acei and/or arb) dose for ≥ 3 months prior to screening with no planned change during screening through week 106. * participants who are receiving sglt2i, deara, mra or era must be on a stable and maximum allowed or tolerated dose for ≥ 3 months prior to screening with no planned change in dose through week 106. exclusion criteria: * diagnosis of rapid progressive glomerulonephritis as measured by egfr loss ≥ 50% over a period of 3 months prior to screening. * secondary igan (eg, due to systemic lupus erythematosus (sle), cirrhosis, or celiac disease; igav-n may be eligible). * concomitant clinically significant renal disease other than igan. * prior use of immunosuppressive treatment within 3 months of screening. * uncontrolled diabetes mellitus with glycosylated hemoglobin (hba1c) \> 8.5%. * henoch-schonlein purpura (igav) requiring systemic immunosuppressive therapy within 12 months of screening. * history of kidney transplant or planned kidney transplant during the treatment period. * splenectomy or functional asplenia. * history of neisseria meningitidis infection. * active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.

Keywords: immunoglobulin a nephropathy igan proteinuria glomerulonephropathy chronic kidney disease ckd
novel real-world methods in social drinkers and aud

Conditions: Alcohol Drinking; Alcohol Abuse; Alcohol Use Disorder

Summary: this research project proposes a novel approach to elucidate the biological adaptations associated with alcohol use disorder and to assess whether such adaptations are predictive of higher alcohol craving in response to both alcohol cues and stressors and higher relapse risk and alcohol use in the real world.

we will use intensive longitudinal data collection and analysis across multiple data streams. we will recruit 25 treatment-seeking individuals with aud and 25 light social drinkers matched on demographically relevant variables (i.e., age, gender, iq, race). we will use smartphones to assess subjects' alcohol use and experiences in real-time via ecological momentary assessment (ema). during three consecutive days of these two weeks, we propose using passive biomonitoring to collect real-time cardiovascular responses, i.e., heart rate variability (hrv), and alcohol use via unobtrusive monitors (i.e., firstbeat bodyguard 2, bactrack skyn) with scheduled salivary cortisol samples. individuals with aud will then be provided with four weeks of behavioral treatment with daily assessments. during the final two weeks of treatment, individuals with aud will complete another three-day period of intensive self-reports, including another 72-hours physiological and salivary cortisol monitoring.

Eligibility criteria:
inclusion criteria: men and women who: 1) are older than 18 years old at the first intake appointment; 2) are fluent in english; 3) are drinking alcohol at levels to match either of the two groups: a. social drinkers: i. must report a past-year history of alcohol use ii. must not meet current aud and may have only met mild aud during their lifetime (not within the past year) iii. provide a negative urine toxicology screen. b. individuals with alcohol use disorder: i. must meet current criteria for aud based on the scid (≤ 2 symptoms in past year); ii. report at least weekly use of alcohol. iii. do not meet criteria for any other substance use disorders other than mild cannabis use disorder. iv. provide a positive urine toxicology screen for alcohol during intake. 5) can provide written informed consent. exclusion criteria: -

Keywords: alcohol use disorder smartphone alcohol cortisol heart rate variability ecological momentary assessment
the effect of early nutrition intervention on the incidence of high-risk patients with gestational diabetes

Conditions: Gestational Diabetes

Summary: the incidence of gestational diabetes increased.the multidisciplinary management of gdm during pregnancy is helpful to improve the pregnancy outcome, but it will occupy huge medical resources.early prediction, diet and exercise interventions can reduce the incidence of gestational diabetes, but there is no reliable way to predict and intervene early.this study is a randomized controlled trials, and aims to use comprehensive prediction method (genetic screening, body composition, clinical risk factors screening) screening the subjects with high gdm risk in early pregnancy, conducting diet and exercise intervention in second trimester and observing the effect on the incidence of gdm and perinatal outcomes.


Eligibility criteria:
inclusion criteria: * early pregnant women (\< 12 weeks) * fasting blood glucose \< / = 5.6 mmol/l and glycosylated hemoglobin \< / = 5.6% * prepregnancy overweight (bmi \> 23.9) or body fat content more than 30% (based on body composition analysis) * no history of major diseases or long-term drug treatment * no obvious physical disabilities, the ability of physical activity is normal * dietary behavior and mental is normal * resident in beijing, early and middle stage pregnancy can be in beijing area to receive regular obstetric examinations * signed informed consent * the following at least one * first-degree relatives family history of diabetes * history of abnormal lipid metabolism or abnormal lipid metabolism * history of polycystic ovary syndrome * history of large for gestational age infant or macrosomia deliver exclusion criteria: * history of gestational diabetes mellitus * clinical glucose metabolism abnormalities * once taking diabetes drugs or insulin injections * a variety of food allergies or food choices serious limitations * exercise during pregnancy contraindication
study to evaluate the effect of a nu skin product and device for brown spots

Conditions: Hyperpigmentation

Summary: the purpose of this study is to determine whether a topical nu skin product with or without a galvanic spa device improves brown spots on the face. the nu skin product will be compared to an over the counter moisturizer and tretinoin cream.


Eligibility criteria:
inclusion criteria: * able to understand and sign informed consent. * able to complete study and comply with study procedures. * caucasian female ages 25-55. * presence of photodamage and lentigines of ii-iii on the glogau photoaging * must be willing to avoid laser and light treatments, treatments with filler, chemical peels, microdermabrasion, botox or any other cosmetic treatment to the face during the duration of the study. * must be willing to avoid changing topical moisturizers and cosmetics during the study. * able to stop any alpha or beta hydroxy acids, topical retinol or retinoid derivatives, topical antioxidants, or any topical product that may interfere with the study 2 weeks prior to the study. exclusion criteria: * cosmetic treatment of face, such as laser or light treatment, filler, botox, microdermabrasion, or chemical peels 6 months prior to study or during study. * current smoker. * pregnant, nursing, or planning to become pregnant during study. * currently taking drugs including oral retinoids or any other medication with a known clinically significant drug interaction with topical tretinoin. * known hypersensitivity to retinoids. history of severe retinoid dermatitis. * history of substance abuse, mental dysfunction, or other factors limiting ability to cooperate with study. * concurrent participation in another clinical study or participation 30 days prior to enrollment that includes exposure to an investigational drug that would interfere with this study. * any disease or condition which would interfere with study participation or unduly increase risk. * presence of an electrically sensitive support system such as a pacemaker. * known history of epilepsy. * presence of metal implants or metal braces on teeth.
neurofunctional correlates of the behavioral modifications associated with tachidino in children with developmental dyslexia

Conditions: Dyslexia, Developmental

Summary: developmental dyslexia (dd) is the most common learning disorder. multiple cognitive and sensory domains contribute to the etiology of dd and develop before reading acquisition. atypical brain functional responses and structural features have been found in the reading developing circuitry. treatments addressing visual-spatial attention and motion perception (visual attention training; vat) are among the most effective interventions in italian children with dd. the vat seems to improve the efficiency of the visual attention system and the magnocellular (m) pathway which is crucial for learning to read. evidence for impaired m function in subjects with dd in the visual striate and extra-striate cortex have been reported. how these treatments affect the brain functionality is still not clear. since dd has a neurobiological basis, it is important to deeply investigate atypical functional responses and structural features in reading-related areas, and to understand how treatments operate at the neuronal level. a growing number of studies investigates structural and functional measures in neurodevelopmental disorders by using high-resolution mri at high field (3t and 7t). similarly, several studies examine the effects of different types of reading training upon brain activity. better understanding of the relationship between structural/functional abnormalities and dd could disentangle the causes of reading difficulties and helps in developing effective treatments. the significance of this study is twofold: 1) neural correlates of treatment: the investigators expect tachidino to specifically affect the underlying neurophysiological functioning which influences reading skills in children with dd; 2) brain signatures: as integrated multi-domain data (behavioral and brain imaging) are complementary to each other, they could enhance the possibility to find unique treatment/brain functioning combinations to evaluate the effectiveness of intervention and to predict the treatment response.


Eligibility criteria:
inclusion criteria: * reading skills (both accuracy and speed) below -2.00 standard deviation exclusion criteria: * no adhd * no contraindications to magnetic resonance
arteriovenous plasma multiomics in patients with disorders of consciousness

Conditions: Disorders of Consciousness; Transient Ischemic Attack

Summary: in order to determine the abnormal cerebral metabolism in the pathological state, we compared the blood of internal jugular vein, superior vena cava and radial artery during central venous catheterization. metabonomics, proteomics and inflammatory factor microarray were used to detect the material differences in arteriovenous blood of patients with disorders of consciousness. at the same time, we concurrently compared it with the peripheral plasma metabolome of two additional patient cohorts: those in-stent restenosis and non-restenosis.

background:it is unclear what substances the brain needs to ingest for its activity under pathological conditions method:the uptake and release of substances by the brain were observed by comparing arterial blood with internal jugular vein blood;the characteristics of brain metabolites were observed by comparing internal jugular vein blood with superior vena cava blood. compared it with the peripheral plasma metabolome of two additional patient cohorts: those in-stent restenosis and non-restenosis. objective:by analyzing different substances, this paper briefly describes the pathological mechanism of patients with disorders of consciousness, and looks for potential prognostic biomarkers.

Eligibility criteria:
inclusion criteria: 1.patients with consciousness disorder caused by various severe brain injuries exclusion criteria: 1. patients who have been judged brain dead 2. there are persistent epileptic activity, inhibition or seizure inhibition patterns 3. recent fever, abnormal liver and kidney function 4. previous history of neurological or mental illness 5. have a history of tumor 6. inflammatory bowel diseases, hyperlipidemia, gastritis

Keywords: plasma metabolism
dexycu (dexamethasone intraocular suspension) 9% retrospective study 001

Conditions: Cataract

Summary: retrospective study to provide clinical outcomes with dexycu (dexamethasone intraocular suspension) 9%.

this retrospective study is intended to provide large-scale, real-world data on clinical outcomes with dexycu (dexamethasone intraocular suspension) 9%.

Eligibility criteria:
inclusion criteria * male and female subjects at least 18 years of age * subjects who underwent cataract surgery from 12mar2019 to 15dec2019 and received dexycu exclusion criteria • subjects who underwent cataract surgery and did not receive dexycu

Keywords: dexycu cataract dexamethasone intraocular suspension
seroma prevention after body contouring procedures

Conditions: Seroma; Abdominoplasty; Complication of Surgical Procedure

Summary: with a prevalence of up to 25%, seroma formation is among the most common complications of body contouring procedures such as abdominoplasty. small amounts of fluid are reabsorbed by the body spontaneously, however, larger seroma volumes need to be evacuated via puncture aspiration to prevent wound healing disturbances and infection, leading to major patient discomfort and a prolonged hospital stay. there is increasing controversy regarding the efficacy of surgical drains in seroma prevention. this study compares the incidence rate of seroma in three study arms with different usage of drains.


Eligibility criteria:
inclusion criteria: * all full-aged patients requiring body contouring procedures in our department who provide oral and written informed consent indicating that they agree to participate in the study exclusion criteria: * minors or patients with a designated health care proxy, revision surgeries, morbid obesity

Keywords: drain usage